Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Hua‐Jay J. Cherng, Guofan Xu, Lei Feng, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Maria Rodriguez, Michael Wang, Fredrick Hagemeister, Chelsea C. Pinnix, Jeremy Ramdial, Samer Srour, Yago Nieto, Katayoun Rezvani, Richard Champlin, Partow Kebriaei, Jason Westin, Homer A. Macapinlac, Elizabeth Shpall, Sairah Ahmed
Publikováno v:
British Journal of Haematology. 200:35-44
Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease. A
Autor:
Loretta J. Nastoupil, Collin K. Chin, Jason R. Westin, Nathan H. Fowler, Felipe Samaniego, Xiaoyun Cheng, Man Chun John Ma, Zhiqiang Wang, Fuliang Chu, Ly Dsouza, Chizobam Obi, Jennifer Mims, Lei Feng, Shouhao Zhou, Michael Green, Richard Eric Davis, Sattva S. Neelapu
Publikováno v:
Blood Advances. 6:1143-1151
PD-1 blockade enhances the function of antitumor T cells and antibody-dependent, cell-mediated cytotoxicity (ADCC) of NK cells. In a single-center, open-label, phase 2 trial, we tested the combination of pembrolizumab, an anti-PD-1 monoclonal antibod
Autor:
Joseph D. Khoury, Sarah A. Milgrom, Loretta J. Nastoupil, Elizabeth J. Shpall, Jillian R. Gunther, Sattva S. Neelapu, Sairah Ahmed, Raphael E Steiner, Maria Gule-Monroe, Ranjit Nair, Karine A. Al Feghali, Jason R. Westin, Chelsea C. Pinnix, Chitra Hosing, Nathan Fowler, Tommy Sheu, Penny Fang, Bouthaina S. Dabaja, Christopher R. Flowers, Paolo Strati, Yago Nieto
Publikováno v:
Leukemia & Lymphoma. 62:2400-2407
This study aimed to assess the prognostic value of baseline disease distribution for patients with the secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy and radiation (RT). 44 patients with seconda
Autor:
Erin Taylor, Felipe Samaniego, Loretta J. Nastoupil, Lei Feng, Sattva S. Neelapu, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Nathan Fowler, Maria Alma Rodriguez, Michelle A. Fanale
Publikováno v:
Leukemia & Lymphoma. 62:58-67
R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with
Autor:
Ian W. Flinn, M. Lia Palomba, Sattva S. Neelapu, Peter Martin, Jutta K. Neuenburg, Loretta J. Nastoupil, Nathan Fowler, Raul Mena, Ranjana H. Advani, Darrin M. Beaupre, Karl Eckert, Sven de Vos, Mark Knapp, Sumeet Bhatia, Richard E. Davis, Robert T. Chen, Melannie Co, Jerry Ping
Publikováno v:
British Journal of Haematology
Summary This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously pl
Autor:
Sattva S. Neelapu, David A. Scheinberg, Saber Tadros, Neeraj Jain, E. De Stanchina, Matthew Durant, Jose Baselga Baselga, Lorena Fontan, Eneda Toska, Oliver Weigert, Cassian Yee, Anas Younes, Ahmet Dogan, Ari Melnick, Aaron Y. Chang, Huan Yang, Anja Mottok, Hsia-Yuan Ying, Loretta J. Nastoupil, Chi-Shuen Chu, Stefan Alig, Robert G. Roeder, Giorgio Inghirami, Patrizia Mondello, Man Chun John Ma, Shailbala Singh, Michael R. Green, Sreejoyee Ghosh, Matt Teater
Publikováno v:
Cancer Discov
CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption of the epige
Autor:
Matthew A. Lunning, Hari P. Miskin, Jonathon B. Cohen, Nathan Fowler, Marshall T. Schreeder, Tanya Siddiqi, Loretta J. Nastoupil, Michael S. Weiss, Jan A. Burger, Christopher R. Flowers, Susan O'Brien, Julie M. Vose, Peter Sportelli, William G. Wierda
Publikováno v:
Blood
Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies. The safety of the next-generation compounds umbralisib, a PI3
Autor:
Carla Casulo, Melissa C Larson, Julianne J Lunde, Thomas M Habermann, Izidore S Lossos, Yucai Wang, Loretta J Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon B Cohen, Brad S Kahl, W Richard Burack, Jean L Koff, Yong Mun, Anthony Masaquel, Mei Wu, Michael C Wei, Ashwini Shewade, Jia Li, James Cerhan, Christopher R Flowers, Brian K Link, Matthew J Maurer
Publikováno v:
Lancet Haematol
Novel therapies for relapsed or refractory follicular lymphoma are commonly evaluated in single-arm studies without formal comparison with other treatments or historical controls. Consequently, rigorously defined treatment outcomes informing expectat
Autor:
Sattva S. Neelapu, Maria Alma Rodriguez, Jason R. Westin, Hubert H. Chuang, Ranjit Nair, Luis Fayad, Raphael E Steiner, Fredrick B. Hagemeister, Hua Jay J. Cherng, Homer A. Macapinlac, Christopher R. Flowers, Loretta J. Nastoupil, Paolo Strati, Hun Ju Lee, Lei Feng, Felipe Samaniego
Publikováno v:
Leuk Lymphoma
Many patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will not respond to platinum-containing salvage chemotherapy. Predicting treatment failure earlier could help clinicians minimize chemotherapy toxicities for non-responde
Autor:
Loretta J, Nastoupil
Publikováno v:
Current hematologic malignancy reportsPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance. 16(1)
Follicular lymphoma is a common indolent non-Hodgkin lymphoma with survival improving in the modern era. Despite favorable responses and improving remission duration, FL remains largely incurable with patterns of relapsing and remitting disease with